Pyridostigmin e without atropine, pyridostigmin e with atropine or neostigmine with atropine were used to antagonise neuro-muscul ar blockade induced by d-tubocurarin e in forty otherwise healthy, female patients recovering from gynaecologica l surgery. Pulse rates fell significantly (P -< 0.01, control heart rate 72 ± 18 beatslmin (M ± SD) to 55 ± 13 beatslmin) at ten minutes after pyridostigmin e (10 mg/70 kg), necessitating administratio n of atropine (1.25 mg/70 kg) by fifteen minutes after pyridostigmin e. After an initial rise in rate, pulse rates also fell significantly (P < 0.01, control heart rate 70± 12 beatslmin to 44 ± 11 beatslmin) at fifteen minutes after injection of neostigmine (2.5 mg/70 kg) with atropine (1.25 mg/70 kg). By contrast when pyrdostigmine and atropine were used together, pulse rates rose and then fell, but mean values never fell below control during a twenty-minute observation period. It was concluded that pyridostigmin e should not be given alone, but requires the use of atropine to prevent bradycardia. This combination may, however, provide a more stable heart rate than that seen with neostigmine and atropine in usual doses, when these drugs are used to antagonise d-tubocurarin e.
INTRODUCTIO N Pyridostigmi ne has been preferred to neostigmine for the treatment of myasthenia gravis, because it has greater effectiveness, longer duration of action, less muscarinic side effects and a wider safety margin between toxic and therapeutic doses. 1 . 2 Katz 1 demonstrated its effectiveness in reversing the muscle relaxation caused by d-tubocurarin e and suggested that because it had less muscarinic action it might be used safely without atropine. We, therefore, attempted to assess the need for the use of atropine with pyridostigmin e comparing the effects on heart rate of pyridostigmin e alone, with equipotent mixtures of pyridostigmin e with atropine and neostigmine with atropine.
METHODS
The patients, all female, were aged between 18 and 50 years (American Society of Anaesthesio logists Physical Status 1) undergoing gynaecologica l procedures. They were anesthetized with thiopentone (2 mg/kg), nitrous oxide:oxygen (2: 1) and phenoperidine (70 j.lg/kg) and paralyzed with d-tubocurarin e (0.5 mg/kg) supplemented with doses necessary to provide satisfactory operating conditions. A further dose of opiate (fentanyl 0.01 j.lg/kg) was given just prior to reversal of muscle paralysis, five minutes after completion of the surgical procedure. The patients were maintained throughout in a state of moderate respiratory alkalosis using mechanical ventilation. Arterial carbon dioxide tension PaC02 was kept in the range 25 to 30 mm Hg.
The patients were divided into four groups of 10. Group A received pyridostigmine with atropine, Group B pyridostigmine alone, while Group C received neostigmine with atropine and Group D physiologic saline as an initial injection. The doses used were: atropine 18 ~g/kg; neostigmine 36 ~g/kg; and pyridostigmine 143 ~g/kg. These were equivalent to 1.25 mg of atropine, 2.5 mg neostigmine and 10 mg of pyridostigmine respectively in a 70 kg individual. The final volume of solution injected was adjusted to 10 ml with the addition of saline. The assignment of the consecutive patients to the four groups was randomized and the experimenters were not informed which drugs had been injected until the end of the 20-minute experimental period.
The electrocardiogram was continuously monitored, and recorded before, during and for 15 minutes after this first reversal injection. At the end of the study period (15 minutes) a second injection was given such that each patient had received both atropine and an anticholinesterase.
Student's t test for paired and unpaired data was used for comparison of the results.
RESULTS
With pyridostigmine given alone (Group B, Table 1 ) there was a progressive slowing of heart rate. The mean reduction in heart rate at ten minutes after the injection in this group (Group B, Table 1 ) was significant when compared with control values (Group Band D, Table 1 ). The lower limit of the 95 per cent confidence range for heart rate at ten minutes after pyridostigmine alone (Group B, Table 1 ) was 29 beats/min. Since such severe slowing of heart rate could be associated with a marked fall in blood pressure and with the possible incidence of potentially serious dysrhythmias, no patient was allowed to suffer a drop in heart rate below 38 beats/min. At such time as heart rate reached this limit, atropine (1.25 mg/70 kg) was administered intravenously. This was necessary, between 10 and 15 minutes after the initial injection in three of our 10 patients given pyridostigmine alone. One of these patients also exhibited first degree heart block which reverted to a normal cardiac rhythm following atropine.
It should be noted that the mean heart rate at fifteen minutes after neostigmine with atropine had slowed to 44 beats/min (Group C, Table  1 ), whereas heart rate remained within normal limits at both 10 and 15 minutes after pyridostigmine with atropine. Extra doses of atropine were given to three of 10 patients in the neostigmine-atropine group. The saline control group (Group D, Table 1 ) was used to exclude any effect of the fentanyl given five minutes prior to the experimental period. Heart rate remained stable for fifteen minutes prior to the second injection of neostigmine with atropine in this group.
DISCUSSION
Because of the profound bradycardia seen after its use, we conclude that it is unsafe to use pyridostigmine alone in doses sufficient to reverse the neuro-muscular blockade induced by d-tubocurarine. Pyridostigmine requires the use of atropine. Why then is pyridostigmine recommended? It may be useful for reversal of neuro-muscular blocking agents after surgery simply because of its long duration of effect. 4 This property is said to be useful in the reversal of neuromuscular blocking agents in patients with severe renal disease. s However, even in this situation neostigmine may still be used,6 since it has been shown that the onset of action of pyridostigmine is slower than that of neostigmine when used for the reversal of pancuronium. Further, others 7 have shown that the clearance of neostigmine is prolonged in the presence of renal failure and thus its action may also be prolonged in this situation. We cannot reach any conclusion about the relative advantages or disadvantages of neostigmine or pyridostigmine in the presence of renal failure from our own study.
We found, however, that heart rate is more stable after pyridostigmine and atropine than after neostigmine and atropine, and this supports the use of pyridostigmine for patients with rate-dependent cardiac output, particularly perhaps children with cardiac disease. Fogdall and Miller, 8 who agree that there is no place for the use of pyridostigmine alone, were unable to show a difference between the cardiac rate effects of neostigmine with atropine and pyridostigmine with atropine because they saw no fall in heart rate after neostigmine. It should be noted that larger doses of pyridostigmine (14.5 mg/70 kg) were used in their study. Subsequent work from the same group4 suggests that 10.75 mg of pyridostigmine is equivalent to 2.5 mg neostigmine, and it is on this basis that we chose to use 10 mg of pyridostigmine. We are unable to explain the difference between Miller's study and ours.
Recently Owen and others 9 showed a lower incidence of arrhythmia after the use of pyridostigmine than after neostigmine. This together with the more stable heart rate we have noted reversing d-tubocurarine with pyridostigmine-atropine may recommend the use of pyridostigmine over neostigmine in certain patient groups.
